347 related articles for article (PubMed ID: 24090287)
1. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.
He D; Guo S; Chen W; Chen X; Yan G; Wang J; Li M; Zhu P; Huang H; Wang Y
BMC Infect Dis; 2013 Oct; 13():458. PubMed ID: 24090287
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
4. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
5. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients.
Kim YJ; Kim K; Hwang SH; Kim SS; Lee D; Cheong JY; Cho SW
Clin Mol Hepatol; 2013 Sep; 19(3):300-4. PubMed ID: 24133668
[TBL] [Abstract][Full Text] [Related]
6. Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B.
Lee IC; Sun CK; Su CW; Wang YJ; Chang HC; Huang HC; Lee KC; Huang YS; Perng CL; Liu YH; Chua CS; Lin YM; Lin HC; Huang YH
Medicine (Baltimore); 2015 Aug; 94(32):e1341. PubMed ID: 26266383
[TBL] [Abstract][Full Text] [Related]
7. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.
Lai CL; Wong DK; Wong GT; Seto WK; Fung J; Yuen MF
JHEP Rep; 2020 Jun; 2(3):100112. PubMed ID: 32462119
[TBL] [Abstract][Full Text] [Related]
8. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
Cao J; Chi H; Yu T; Li Z; Hansen BE; Zhang X; Zhong C; Sun J; Hou J; Janssen HLA; Peng J
J Infect Dis; 2017 Feb; 215(4):581-589. PubMed ID: 28329347
[TBL] [Abstract][Full Text] [Related]
9. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
[TBL] [Abstract][Full Text] [Related]
10. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
[TBL] [Abstract][Full Text] [Related]
11. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
[TBL] [Abstract][Full Text] [Related]
12. Current Trend in Antiviral Therapy for Chronic Hepatitis B.
Chien RN; Liaw YF
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216027
[TBL] [Abstract][Full Text] [Related]
13. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
[TBL] [Abstract][Full Text] [Related]
14. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
[TBL] [Abstract][Full Text] [Related]
15. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status.
Liu F; Liu ZR; Li T; Liu Y; Zhang M; Xue Y; Zhang LX; Ye Q; Fan XP; Wang L
J Dig Dis; 2018 Sep; 19(9):561-571. PubMed ID: 30098114
[TBL] [Abstract][Full Text] [Related]
16. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.
Jeng WJ; Sheen IS; Chen YC; Hsu CW; Chien RN; Chu CM; Liaw YF
Hepatology; 2013 Dec; 58(6):1888-96. PubMed ID: 23744454
[TBL] [Abstract][Full Text] [Related]
17. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
Hirode G; Choi HSJ; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong G; Brakenhoff SM; Chien RN; Feld J; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
Gastroenterology; 2022 Mar; 162(3):757-771.e4. PubMed ID: 34762906
[TBL] [Abstract][Full Text] [Related]
18. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
Zheng Z; Liao W; Liu L; Cai S; Zhu H; Yin S
Biomed Pharmacother; 2020 Feb; 122():109698. PubMed ID: 31918272
[TBL] [Abstract][Full Text] [Related]
19. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.
Chi H; Hansen BE; Yim C; Arends P; Abu-Amara M; van der Eijk AA; Feld JJ; de Knegt RJ; Wong DK; Janssen HL
Aliment Pharmacol Ther; 2015 May; 41(9):867-76. PubMed ID: 25752878
[TBL] [Abstract][Full Text] [Related]
20. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study.
Seto WK; Hui AJ; Wong VW; Wong GL; Liu KS; Lai CL; Yuen MF; Chan HL
Gut; 2015 Apr; 64(4):667-72. PubMed ID: 24833635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
